RC2NB

Yes👍 from @SofiaSandgren1 @JensKuhle @RC2NB @UniBasel: Blood NfL can provide information on disease activity, prognosis and treatment response, both in drug development trials and in personalised medicine in #MultipleSclerosis. 🔽 journals.sagepub.com/doi/abs/10.117… 2/🧵

John Dystel Prize for Multiple Sclerosis Research awarded to Dr. Ludwig Kappos for his transformative contributions to MS research eurekalert.org/news-releases/…

Our latest Annual Report is out 🚀 Full of insights, milestones, and momentum through research, data innovation, and collaboration. 👉 Get it here: rc2nb.ch/media-and-down…

In #MultipleSclerosis, treatment effects on blood neurofilament light chain #NfL are moderately associated with therapeutic effects on relapses and MRI lesions. A meta-regression of randomized controlled trials from @RC2NB @UniBasel_en @unige_en ▶️ journals.sagepub.com/doi/abs/10.117…

OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in the care of people with #MultipleSclerosis. 🔓MSJ-ETC study from @Unispital_USZ @RC2NB ▶️ journals.sagepub.com/doi/full/10.11…

Deep learning can automate the classification of paramagnetic rim and remyelinated lesions in #MultipleSclerosis, guiding personalized treatment decisions. Study from @CristinaGranzi2 @RC2NB ▶️ journals.sagepub.com/doi/abs/10.117…

Check out his profile here:webofscience.com/wos/author/rec…

🎉 Congratulations to Prof. @JensKuhle , Head of the MS Centre @usb_ch and Group Leader @RC2NB, for being named one of Clarivate’s Highly Cited Researchers 2025, ranking among the top 1% most cited scientists worldwide. #HighlyCited2025 #ResearchExcellence #Neuroscience

New study in Science Translational Medicine (@ScienceMagazine) from @akproebstel and colleagues reveals distinct immune signatures in MOG antibody–associated disease (MOGAD), distinguishing it from MS. Researchers from Zurich, Munich, Toulouse, Lyon, Bonn & Basel (@DepBiomedicine, @DKFBasel, @RC2NB) uncover key immune differences shaping future therapies. 👉🏻 Link: science.org/doi/10.1126/sc… #MOGAD #MSResearch #Neuroinflammation

New study led by David Leppert, Roberto Furlan & @JensKuhle shows that specific CSF markers can distinguish MOGAD & NMOSD from MS. A fast, biology-driven approach for accurate diagnosis in acute demyelination. academic.oup.com/brain/advance-… #MS #MOGAD #NMOSD #Biomarkers

🧪 New data from the phase 3 POINT study: combining ponesimod + dimethyl fumarate in relapsing MS did not improve relapse rate, but reduced MRI lesion activity vs DMF alone. Safety was consistent with known profiles. 📄 sciencedirect.com/science/articl…

MSIF is proud to announce Professor Ludwig Kappos as the 2025 #CharcotAward recipient, honouring a lifetime of impact in #MSResearch. 🏆🔬 From pioneering treatments to mentoring researchers worldwide, his legacy is global. 🌎 Read more: msintfederation.org/4ncra5K   @RC2NB

🚀 Our new website is live! Explore RC2NB's research, people & purpose — now at RC2NB.ch 🧠✨ 🎬 Watch the RC2NB Welcome Video for a glimpse into our world. ▶️ vimeo.com/1090750659/132… #RC2NB #Neuroimmunology #MSResearch #WebsiteLaunch

Functional System scores and their corresponding subscores, Ambulation scores and EDSS scores revealed different patterns of disability in #MultipleSclerosis. Machine learning study using EXPAND trial from @RC2NB @UniBasel_en @UniSpitalBasel ▶️ journals.sagepub.com/doi/full/10.11…

🧠 New in Neurol Neuroimmunol Neuroinflamm: CSF TNF markers + early gray matter damage predict PIRA in early RRMS. Key predictors: sTNFR1, sTNFR2, LIGHT, cortical lesions, thalamic atrophy. 🔗pubmed.ncbi.nlm.nih.gov/40311103/#&gid… #MS #PIRA #Neuroinflammation #MRI #CSF #MultipleSclerosis

Just 24 participants to go: Our Swisswide pragmatic #MultiSCRIPT trial is close to reaching 915 in about a year. Only possible through full embedding in routine care and with an outstanding team @RC2NB and #SMC and the wonderful support of our patients. multiscript.rc2nb.ch

In RC2NB’s Annual Report, real patient stories highlight why personalized treatments & cutting-edge research matter. Together, we’re shaping the future of MS care. #MS #Research #PatientVoices

We are pleased to present the @RC2NB Annual Report 2024, highlighting a year of progress, key milestones, and scientific advancements across our four core workstreams. 📖 Read the full report here: rc2nb.ch/wp-content/upl…

Feb 11 – International Day of Women & Girls in Science! 🚀 At #RC2NB & @ThINk_Basel , this day is every day. Leading the way? Prof. Cristina Granziera, championing brilliant women who shape the future of #STEM.🔬💡 #WomenInScience #IDWGS #MSresearch

@RC2NB joined the MS State of the Art Symposium 2025 on "Lifestyle in MS: Sports, Nutrition, & Brain Health." Proud to see @ThINk_Basel & @JensKuhle represent RC2NB, with our team sharing research on: 🔬 MultiSCRIPT 🔬 Complement activation in MS 🔬 B cell therapies